Search results
Showing 16 to 30 of 46 results for copd exacerbation
for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable...
NG115/8 Question Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics,...
preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with...
This indicator covers the percentage of patients with COPD on the register, who have had a review in the preceding 12 months, including a record of the number of exacerbations and an assessment of breathlessness using the Medical Research Council dyspnoea scale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM170
In development Reference number: GID-TA10239 Expected publication date: 06 August 2026
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
Question Mucolytic therapy:- In people with COPD, does mucolytic drug therapy prevent exacerbations in comparison with...
Awaiting development Reference number: GID-TA11944 Expected publication date: TBC
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Digital technologies to support self-management of asthma: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 30 April 2026
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in...
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.